With the support of our advanced protein engineering platform that we have established for many years, Creative BioMart has successfully designed a variety of platforms for different applications to produce special proteins based on the directed evolution strategy. Creative BioMart provides customers with a wide range of engineering of therapeutic proteins services, which through many diverse variety of protein therapeutics with improved activity, specificity, stability, pharmacodynamics, pharmacokinetics, reduced immunogenicity and improved productivity.

There are two main types of drugs on the market: small molecule drugs and protein therapeutic drugs. Although the former is currently the main therapeutic drug, the impact of protein therapy is increasing due to advances in recombinant DNA technology and a deepening understanding of disease pathology. The protein engineering strategy has revolutionized the medical field through the efforts of the era of protein therapeutics. Protein therapeutics according to its molecular type, including antibody-based drugs, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, Fc fusion proteins, growth factors, hormones, interferons, interleukins and thrombolytic drugs, etc. Protein drugs are usually large in size and have a larger surface area to contact the target protein, making them an indispensable therapeutic tool for the treatment of human diseases.

Fig 1. Data-driven engineering of protein therapeutics. (Faber MS, et al., 2019)

Services

More and more engineered protein therapies are currently being developed and tested for use in clinical trials and on the market. These proteins can achieve desired properties through specific mutations, fusion partners, or chemical modifications. Creative BioMart has successfully established a therapeutic protein engineering platform to design a variety of protein therapies to solve previously incurable debilitating diseases, such as chronic renal failure, dwarfism and infertility. Our engineering of therapeutic proteins services significantly improve the effectiveness and safety of existing protein therapies, and allow the production of entirely new types of proteins and modes of action. The therapeutic proteins we successfully designed include but are not limited to:

• Engineering of Therapeutic Antibodies
• Engineering of Therapeutic Protein Hormones
• Engineering of Therapeutic Coagulation Factors
• Engineering of Therapeutic Enzyme
• Engineering of Therapeutic Cytokines and Receptors
• Engineering of Therapeutic T Cell Receptors
• Engineering of Therapeutic Major Histocompatibility Complex Proteins
• Engineering of Therapeutic TCR-Like Antibodies

Strategies of Engineering of Therapeutic Proteins

Protein therapeutics needs a lot of improvement in drug target identification, protein engineering and design, protein expression and purification, and drug delivery. In order to solve these problems, our scientists are committed to developing various strategies for designing effective protein therapeutics. For your project, we will choose the right strategy for you.

• Strategies for improving pharmacokinetics: we use a variety of strategies including fusion, glycosylation, and chemical modification to improve the efficacy of therapeutic proteins in the human body. Recombinant DNA technology can fuse the protein of interest with endogenous human proteins, thereby increasing the effective size of the protein and reducing the clearance rate in the kidney. Glycosylation helps enhance the solubility of proteins. Polyethylene glycol (PEG) modification increases the half-life of serum proteins.
• Strategies for reducing immunogenicity: we have developed various strategies to reduce immunogenicity. Polyethylene glycol (PEG) protects the immune response sites on the recombinant protein from being recognized by antibodies or surface receptors. Changing the main sequence of the therapeutic protein can also help reduce immunogenicity. In addition, recognition and elimination of antibodies and T-cell epitopes and class II MHC agretopes are used to reduce the immunogenicity of next-generation protein therapies.
• Genetic Engineering Strategies: we use the three strategies of rational design, directed evolution and semi-rational design to change the physical and chemical properties of proteins and/or create new functions, and apply them to protein therapeutics.

Service Principle

Creative BioMart is based on innovative, pragmatic and honest, adhering to the tenet of "Quality is our life, providing customers with the best quality service", providing customized services to customers around the world.

We will be glad to discuss details of intended interaction studies with you and develop experimental strategies/methods tailored to your requirement. Our customer service representatives are enthusiastic and trustworthy 24 hours a day, Monday to Friday. Please do not hesitate to contact us for more information or to discuss in detail, if you are interested in our services.

References

1. Faber MS, Whitehead TA. (2019) Data-driven engineering of protein therapeutics. Curr Opin Biotechnol. 60: 104-110.
2. McCafferty J, Glover D R. (2000) Engineering therapeutic proteins. Current opinion in structural biology. 10(4): 417-420.

• Design and Engineering of Synthetic Binding Proteins Using Nonantibody Scaffolds
• Enzyme Engineering
• Protein Engineered Biomaterials
• Protein Engineering Using Noncanonical Amino Acids